The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma

Modern Pathology

Volumn 29, Issue 1, 2016, Pages 14-24

  Singhi, Aatur D ^a   Krasinskas, Alyssa M ^b   Choudry, Haroon A ^c   Bartlett, David L ^c   Pingpank, James F ^c   Zeh, Herbert J ^c   Luvison, Alyssa ^a   Fuhrer, Kimberly ^a   Bahary, Nathan ^c   Seethala, Raja R ^a   Dacic, Sanja ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAP1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; NF2 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOCUS; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR INVASION; DISEASE FREE SURVIVAL; LUNG TUMOR; MESOTHELIOMA; METABOLISM; MIDDLE AGED; MORTALITY; NEUROFIBROMATOSIS TYPE 2; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEUROFIBROMATOSIS 2; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84952717744     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.121     Document Type: Article

References (47)

1. Hesdorffer ME, Chabot J, DeRosa C et al. Peritoneal mesothelioma. Curr Treat Options Oncol 2008;9: 180-190.
2. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004;159:107-112.
3. Bridda A, Padoan I, Mencarelli R et al. Peritoneal mesothelioma: a review. MedGenMed 2007;9:32.
4. Acherman YI, Welch LS, Bromley CM et al. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269-273.
5. Antman KH. Current concepts: malignant mesothelioma. N Engl J Med 1980;303:200-202.
6. Antman KH, Osteen RT, Klegar KL et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet 1985;2:977-981.
7. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg 1999;384:576-587.
8. Yan TD, Welch L, Black D et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007;18:827-834.
9. Alexander HR Jr., Bartlett DL, Pingpank JF et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013;153:779-786.
10. Feldman AL, Libutti SK, Pingpank JF et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-4567.
11. Magge D, Zenati MS, Austin F et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014;21: 1159-1165.
12. Loggie BW, Fleming RA, McQuellon RP et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999-1003.
13. Deraco M, Nonaka D, Baratti D et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006;13: 229-237.
14. Yan TD, Deraco M, Baratti D et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multiinstitutional experience. J Clin Oncol 2009;27: 6237-6242.
15. Sugarbaker PH, Welch LS, Mohamed F et al. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003;12:605-621.
16. Guo G, Chmielecki J, Goparaju C et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015;75:264-269.
17. Bott M, Brevet M, Taylor BS et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21. 1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-672.
18. Nasu M, Emi M, Pastorino S et al. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 2015;10:565-576.
19. Cheng JQ, Jhanwar SC, Klein WM et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547-5551.
20. Bianchi AB,Mitsunaga SI, Cheng JQ et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995;92:10854-10858.
21. Illei PB, Rusch VW, Zakowski MF et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9: 2108-2113.
22. Dacic S, Kothmaier H, Land S et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 2008;453:627-635.
23. Chiosea S, Krasinskas A, Cagle PT et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008;21:742-747.
24. Kobayashi N, Toyooka S, Yanai H et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008;62: 120-125.
25. Lopez-Rios F, Chuai S, Flores R et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006;66:2970-2979.
26. Thurneysen C, Opitz I, Kurtz S et al. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009;64:140-147.
27. Xiao GH, Gallagher R, Shetler J et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 2005;25:2384-2394.
28. Fleury-Feith J, Lecomte C, Renier A et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 2003; 22:3799-3805.
29. Sheffield BS, Hwang HC, Lee AF et al. BAP1 Immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol 2015;39:977-982.
30. Farzin M, Toon CW, Clarkson A et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 2015;47:302-307.
31. Baumann F, Flores E, Napolitano A et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 2015;36: 76-81.
32. Krasinskas AM, Bartlett DL, Cieply K et al. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol 2010;23:531-538.
33. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82: 359-374.
34. Mohamed F, Cecil T, Moran B et al. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 2011;18:e84-e96.
35. Chung CT, Santos Gda C, Hwang DM et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 2010;63:630-634.
36. Tochigi N, Attanoos R, Chirieac LR et al. p16 Deletion in sarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med 2013;137:632-636.
37. Wu D, Hiroshima K, Matsumoto S et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol 2013;139:39-46.
38. Tsao AS, Wistuba I, Roth JA et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.
39. Browne K, Smither WJ. Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 1983;40:145-152.
40. Borczuk AC, Cappellini GC, Kim HK et al. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 2007;26: 610-617.
41. Trupiano JK, Geisinger KR, Willingham MC et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476-481.
42. Jongsma J, van Montfort E, Vooijs M et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008;13:261-271.
43. Deraco M, Bartlett D, Kusamura S et al. Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008;98:268-272.
44. Yan TD, Deraco M, Elias D et al. A novel tumor-nodemetastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database∗Cancer 2011;117:1855-1863.
45. Zauderer MG, Bott M, McMillan R et al. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol 2013;8:1430-1433.
46. McGregor S, Dunning R, Hadi D et al. BAP1 loss portends improved prognosis in malignant pleural mesothelioma due to frequent association with epithelioid morphology. Mod Pathol 2015;28:484A.
47. Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg 2009;1: 38-48.